期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 123, 期 8, 页码 1764-1772出版社
WILEY
DOI: 10.1002/jso.26464
关键词
apoptosis; cell proliferation; immunohistochemistry; overall survival
资金
- National Institute of Health [R01CA038173, R01CA054807]
The study revealed a correlation between high stathmin expression and CRC metastasis as well as worse prognosis, along with increased cell proliferation. These findings suggest stathmin as a potential marker for increased risk and treatment in CRC patients.
Objectives To evaluate the relationship between stathmin expression and clinical outcome in colorectal cancer (CRC). Background Stathmin is a phosphoprotein involved in the regulation of microtubule dynamics and integration of intracellular signaling pathways. Stathmin has been implicated in the tumorigenesis of several cancers and is a potential therapeutic target. Methods Stathmin expression was evaluated in 25 metastatic CRC (mCRC) patients by immunohistochemistry (IHC). Ki67 IHC and TUNEL assay were also evaluated in mCRC for cell proliferation and apoptosis. Results High expression of stathmin was correlated with CRC metastasis (p = .0084), and significantly worse overall survival (OS) in CRC patients (p = .036). There was a significant increase in cell proliferation and a decrease in apoptosis in liver metastasis compared with CRC primary tumors as determined by Ki67 IHC and TUNEL assay (p < .0001). We also observed a significant positive correlation between stathmin level and cell proliferation in both CRC primary tumor and liver metastasis (p = .0429 to 0.0451; r = .4236 to .4288). Conclusion Stathmin expression correlated with worse patient prognosis in mCRC patients and positively correlated with increased cell proliferation. Together, our findings indicate stathmin as a novel potential marker for increased risk of CRC-specific mortality and identify stathmin as an attractive therapeutic target for the treatment of mCRC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据